Vanda Pharmaceuticals Inc. (VNDA) Earnings History
Annual and quarterly earnings data from 2004 to 2025
Loading earnings history...
VNDA EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
VNDA Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 94.0% | -70.0% | -102.0% |
| 2024 | 94.3% | -20.5% | -9.5% |
| 2023 | 92.3% | -7.2% | 1.3% |
| 2022 | 90.5% | 2.5% | 2.5% |
| 2021 | 90.5% | 15.7% | 12.3% |
Download Data
Export VNDA earnings history in CSV or JSON format
Free sign-in required to download data
Vanda Pharmaceuticals Inc. (VNDA) Earnings Overview
As of May 8, 2026, Vanda Pharmaceuticals Inc. (VNDA) reported trailing twelve-month net income of -$240M, reflecting -1068.8% year-over-year growth. The company earned $-4.03 per diluted share over the past four quarters, with a net profit margin of -102.0%.
Looking at the long-term picture, VNDA's historical earnings data spans multiple years. The company achieved its highest annual net income of $116M in fiscal 2019.
Vanda Pharmaceuticals Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SUPN (-$29M net income, -5.4% margin), PTCT (-$187M net income, 39.4% margin), ACAD ($376M net income, 36.5% margin), VNDA has room to improve margins relative to the peer group. Compare VNDA vs SUPN →
VNDA Earnings vs Peers
Earnings metrics vs comparable public companies
VNDA Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$220M | -1066.5% | -$151M | $-3.74 | -102.0% | -70.0% |
| 2024 | -$19M | -853.3% | -$41M | $-0.32 | -9.5% | -20.5% |
| 2023 | $3M | -60.0% | -$14M | $0.04 | 1.3% | -7.2% |
| 2022 | $6M | -81.1% | $6M | $0.11 | 2.5% | 2.5% |
| 2021 | $33M | +42.1% | $42M | $0.58 | 12.3% | 15.7% |
| 2020 | $23M | -79.8% | $27M | $0.42 | 9.4% | 11.0% |
| 2019 | $116M | +358.4% | $23M | $2.11 | 50.9% | 10.0% |
| 2018 | $25M | +261.9% | $22M | $0.48 | 13.1% | 11.3% |
| 2017 | -$16M | +13.6% | -$17M | $-0.35 | -9.4% | -10.2% |
| 2016 | -$18M | +54.8% | -$19M | $-0.41 | -12.3% | -12.7% |
See VNDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VNDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare VNDA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonVNDA — Frequently Asked Questions
Quick answers to the most common questions about buying VNDA stock.
Is VNDA growing earnings?
VNDA EPS fell to $-4.03, with earnings declining -1068.8%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-240M.
What are VNDA's profit margins?
Vanda Pharmaceuticals Inc. net margin is -102.0%, with operating margin at -70.0%. Below-average margins reflect competitive or cost pressures.
How consistent are VNDA's earnings?
VNDA earnings data spans 2004-2025. The declining earnings trend is -1068.8% YoY. Historical data enables comparison across business cycles.